Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena

Archives of Gynecology and Obstetrics

Volumn 290, Issue 6, 2014, Pages 1079-1092

  Rondanelli, Mariangela ^a   Perna, Simone ^a   Faliva, Milena ^a   Monteferrario, Francesca ^a   Repaci, Erica ^a   Allieri, Francesca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adipokines; Dietary management; Dietary supplement; Insulin resistance; Overweight; Polycystic ovary syndrome

Indexed keywords

ADIPONECTIN; CHROMIUM; CHROMIUM PICOLINATE; COLECALCIFEROL; COPPER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LEPTIN; MAGNESIUM; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; VITAMIN D; ADIPOCYTOKINE;

CALORIC INTAKE; COPPER BLOOD LEVEL; DIET SUPPLEMENTATION; DIET THERAPY; FEMALE; FEMALE FERTILITY; FISH; FOOD COMPOSITION; FOOD INTAKE; GLYCEMIC INDEX; HUMAN; HYPERANDROGENISM; HYPOMAGNESEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW CARBOHYDRATE DIET; MENSTRUAL CYCLE; MENSTRUATION; METABOLIC DISORDER; MINERAL DEFICIENCY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIMARY AMENORRHEA; REPRODUCTION; REVIEW; SECONDARY AMENORRHEA; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ADULT; BLOOD; COMPLICATION; DIET; DRUG EFFECTS; LIFESTYLE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ADIPOKINES; ADULT; DIET; ENERGY INTAKE; FEMALE; GLYCEMIC INDEX; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; LIFE STYLE; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS;

EID: 84920964464     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3433-z     Document Type: Review

References (164)

1. Calvo AM, San Millan RM, Sancho JL, Avila SJ, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434–2438
2. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800
3. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R (2011) Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219–231
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2003) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47
5. Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223–1236
6. Solomon CG (1999) The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 28:247–263
7. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65:499–507
8. Jakubowicz DJ, Nestler JE (1997) 17 alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 82:556–560
9. Plymate SR, Matej LA, Jones RE, Friedl KE (1998) Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460–464
10. Nestler JE, Powers LP, Matt DW et al (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83–89
11. Utsunomiya T, Taniguchi I, Sadanaga A, Iwasato K, Mizoguchi Y, Terawaki S (1993) Insulin resistance in non-obese patients with polycystic ovary syndrome. Jpn J Fertil Steril 38:77–81
12. Rosenfield RL, Barnes RB, Ehrmann DA (1994) Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 79:1686–1692
13. Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ 2001:3–68
14. Yildiz BO, Knochenhauer ES, Azziz R (2008) Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93:162–168
15. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935
16. Peppard HR, Marfori J, Iuorno MJ, Nestler JE (2001) Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24:1050–1052
17. Lim SS, Norman RJ, Davies MJ, Moran LJ (2013) The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 14:25–109
18. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R (2002) Obesity and the polycystic ovary syndrome. Int J Obes Metab Disord 26:883–896
19. DeUgarte CM, Bartolucci AA, Azziz R (2005) Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83:1454–1460
20. Carmina E, Lobo RA (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82:661–665
21. Azziz R, Carmina E, Dewailly D et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488
22. Carmina E, Bucchieri S, Esposito A (2007) Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500–2505
23. Diamanti-Kandarakis E (2006) Insulin resistance in PCOS. Endocrine 30:13–17
24. Geisthövel F (2010) Novel systematics of nomenclature and classification of female functional androgenization (including polycystic ovary syndrome and non-classic congenital adrenal hyperplasia). J Reprod Med Endokrinol 7:6–26
25. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ (2009) Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 24:710
26. Lord JM, Flight IH, Norman RJ (2003) Insulin sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3:CD003053
27. Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F (2005) Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90(7):4068–4074
28. Palomba S, Orio F Jr, Nardo LG, Falbo A, Russo T, Corea D, Doldo P, Lombardi G, Tolino A, Colao A, Zullo F (2004) Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 89(10):4801–4809
29. Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC (2004) Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 81(2):355–360
30. Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M (2005) Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 10(1):100–104
31. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, Elsenbruch S, Kimmig R, Mann K, Janssen OE (2007) Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 157(5):669–676
32. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97:28–38
33. Panidis D, Tziomalos K, Chatzis P, Papadakis E, Delkos D, Tsourdi EA, Kandaraki EA, Katsikis I (2013) Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. Eur J Endocrinol 168(2):145–152
34. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, Johnston DG, Franks S (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 39(3):351–355
35. Gill S, Taylor AE, Martin KA, Welt CK, Adams JM, Hall JE (2001) Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome. J Clin Endocrinol Metab 86(6):2428–2436
36. Cupisti S, Kajaia N, Dittrich R, Duezenli H, Beckmann M W, Mueller A (2008) Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 158(5):711–719. doi:10.1530/EJE-07-0515
37. Strowitzki T, Capp E, von Eye Corleta H (2010) The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. Eur J Obstet Gynecol Reprod Biol 149(2):178–181. doi:10.1016/j.ejogrb.2009.12.024
38. Wang JX, Davies MJ, Norman RJ (2001) Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 16(12):2606–2609
39. Boomsma CM, Fauser BC, Macklon NS (2008) Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 26(1):72–84. doi:10.1055/s-2007-992927
40. Eppig JJ, O’Brien MJ, Pendola FL, Watanabe S (1998) Factors affecting the developmental competence of mouse oocytes grown in vitro: follicle-stimulating hormone and insulin. Biol Reprod 59(6):1445–1453
41. Galal A, Mitwally MF (2009) Insulin sensitizers for women with polycystic ovarian syndrome. Expert Rev Endocrinol Metab 4:183–192
42. Dumesic DA, Schramm RD, Peterson E, Paprocki AM, Zhou R, Abbott DH (2002) Impaired developmental competence of oocytes in adult prenatally androgenized female rhesus monkeys undergoing gonadotropin stimulation for in vitro fertilization. J Clin Endocrinol Metab 87(3):1111–1119
43. Tao Z, Yan L (2005) Luteinizing hormone and insulin inducing earlier and excess expression of luteinizing hormone receptor messenger ribonucleic acids in granulosa cells of polycystic ovary syndrome. Fertil Steril 84(Suppl):S426–S427
44. Diamanti-Kandarakis E (2008) Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 10:e3
45. Jabara S, Coutifaris C (2003) In vitro fertilization in the PCOS patient: clinical considerations. Semin Reprod Med 21(3):317–324
46. Cano F, García-Velasco JA, Millet A, Remohí J, Simón C, Pellicer A (1997) Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women. J Assist Reprod Genet 14(5):254–261
47. Kezele PR, Nilsson EE, Skinner MK (2002) Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition. Mol Cell Endocrinol 192(1–2):37–43
48. Wood JR, Dumesic DA, Abbott DH, Strauss JF (2007) Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 92:705–713. doi:10.1210/jc.2006-2123
49. González F, Rote NS, Minium J, Kirwan JP (2006) Increased activation of nuclear factor kB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 91:1508–1512
50. Piotrowski PC, Rzepczynska IJ, Kwintkiewicz J, Duleba AJ (2005) Oxidative stress induces expression of CYP11A, CYP17, STAR and 3bHSD in rat theca-interstitial cells. J Soc Gynecol Invest 12(2 Suppl):319A
51. González F, Minium J, Rote NS, Kirwan JP (2005) Hyperglycemia alters tumor necrosis factor-a release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:5336–5342
52. González F, Rote NS, Minium J, Kirwan JP (2006) In vitro evidence that hyperglycemia stimulates tumor necrosis factor-a release in obese women with polycystic ovary syndrome. J Endocrinol 188:521–529
53. González F, Rote NS, Minium J, Kirwan JP (2006) Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91:336–340
54. González F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 58:954–962
55. Chazenbalk G, Trivax BS, Yildiz BO (2010) Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. J Clin Endocrinol Metab 95:935–942
56. Carmina E, Orio F, Palomba S (2005) Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 152:389–394
57. Chen X, Jia X, Qiao J, Guan Y, Kang J (2013) Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol 50:21–37
58. Carmina E (2013) Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 40:40–50
59. Chabrolle C, Tosca L, Ramé C, Lecomte P, Royère D, Dupont J (2009) Adiponectin increases insulin-like growth factor l-induced progesterone and estradiol secretion in human granulosa cells. Fertil Steril 92:1988–1996
60. Pusalkar M, Meherji P, Gokral J, Savardekar L, Chinnaraj S, Maitra A (2010) Obesity and polycystic ovary syndrome: association with androgens, leptin and its genotypes. Gynecol Endocrinol 26:874–882
61. Comim FV, Hardy K, Franks S (2013) Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome. PLoS ONE 18(8):e80416
62. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G (2003) Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 18:1790–1796
63. Ardawi MS, Rouzi AA (2005) Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 83:1708–1716
64. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchón R, Luque-Ramírez M, San Millán JL (2006) Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 21(9):2257–2265
65. Pinhas-Hamiel O, Singer S, Pilpel N, Koren I, Boyko V, Hemi R, Pariente C, Kanety H (2009) Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 71(6):823–827. doi:10.1111/j.1365-2265.2009.03604.x
66. Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G et al (2011) Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 96(2):E304–E311. doi:10.1210/jc.2010-1290
67. Shin HY, Lee DC, Lee JW (2011) Adiponectin in women with polycystic ovary syndrome. Korean J Fam Med 32(4):243–248. doi:10.4082/kjfm.2011.32.4.243
68. Lecke SB, Mattei F, Morsch DM, Spritzer PM (2011) Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril 95(6):2044–2049. doi:10.1016/j.fertnstert.2011.02.041
69. Toulis KA, Gouli DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, Papadima I, Panidis D (2009) Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 15:297–307. doi:10.1093/humupd/dmp006
70. Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769
71. Hossam OH (2013) Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. J Obstet Gynaecol Res 39:1596–1603
72. Considine RV, Caro JF (1997) Leptin and the regulation of body weight. Int J Biochem Cell Biol 29:1255–1272
73. Muoio DM, Lynis DG (2002) Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 16:653–666
74. Bjorbaek C, Kahn BB (2004) Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 59:305–331
75. Margetic S, Gazzola C, Pegg GG, Hill RA (2002) Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26:1407–1433
76. Brzechffa PR, Jakimiuk AJ, Agarwal SK, Weitsman SR, Buyalos RP, Magoffin DA (1996) Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 81(11):4166–4169
77. Vicennati V, Gambineri A, Calzoni F, Casimirri F, Macor C, Vettor R, Pasquali R (1998) Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47(8):988–992
78. Pehlivanov B, Mitkov M (2009) Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 14(2):153–159. doi:10.1080/13625180802549962
79. Yildizhan R, Ilhan GA, Yildizhan B, Kolusari A, Adali E, Bugdayci G (2011) Serum retinol binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and non-obese young women with polycystic ovary syndrome. Fertil Steril 96:246–250
80. Chapman IM, Wittert GA, Norman RJ (1997) Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. Clin Endocrinol (Oxf) 46(2):175–181
81. Rouru J, Anttila L, Koskinen P, Penttilä TA, Irjala K, Huupponen R, Koulu M (1997) Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82(6):1697–1700
82. Gennarelli G, Holte J, Wide L, Berne C, Lithell H (1998) Is there a role for leptin in the endocrine and metabolic aberrations of polycystic ovary syndrome? Hum Reprod 13(3):535–541
83. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA (2009) Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril 1(4 Suppl):1332–1335. doi:10.1016/j.fertnstert.2008.03.007
84. Wang P, Holst C, Astrup A et al (2012) Blood profiling of proteins and steroids during weight maintenance with manipulation of dietary protein level and glycaemic index. Br J Nutr 107:106–119
85. Svendsen PF, Christiansen M, Hedley PL, Nilas L, Pedersen SB, Madsbad S (2012) Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertil Steril 98(1):235–241. doi:10.1016/j.fertnstert.2012.03.056
86. Stofkova A (2010) Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 44:25–36
87. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS (2006) Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 91(12):5022–5028
88. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM (2007) Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 88(2):401–405
89. Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, Wolczynski S, Gorska M (2007) Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 22(7):1824–1829
90. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A, Gerou S, Diamanti-Kandarakis E (2008) Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 19(6):406–412. doi:10.1016/j.ejim.2007.05.014
91. Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y (2010) Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril 93(3):880–884. doi:10.1016/j.fertnstert.2008.10.058
92. Plati E, Kouskouni E, Malamitsi-Puchner A, Boutsikou M, Kaparos G, Baka S (2010) Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril 94(4):1451–1456. doi:10.1016/j.fertnstert.2009.04.055
93. Seow KM, Hwang JL, Wang PH, Ho LT, Juan CC (2011) Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum Reprod 26(10):2869–2873. doi:10.1093/humrep/der267
94. Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, Tsourdi E, Panidis D (2012) Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obes Facts 5(4):495–504. doi:10.1159/000341579
95. Güdücü N, İşçi H, Görmüş U, Yiğiter AB, Dünder I (2012) Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 28(8):619–623. doi:10.3109/09513590.2011.650749
96. Lajunen TK, Purhonen AK, Haapea M, Ruokonen A, Puukka K, Hartikainen AL et al (2012) Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 42(3):321–328. doi:10.1111/j.1365-2362.2011.02586.x
97. Olszanecka-Glinianowicz M, Madej P, Zdun D, Bożentowicz-Wikarek M, Sikora J, Chudek J, Skałba P (2012) Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 162(1):55–61. doi:10.1016/j.ejogrb.2012.01.026
98. Kasim-Karakas SE, Almario RU, Cunningham W (2009) Effects of protein versus simple sugar intake on weight loss in polycystic ovary syndrome (according to the National Institutes of Health criteria). Fertil Steril 92:262–270
99. Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ (2007) C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 92:2944–2951
100. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS (2004) A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 81:630–637
101. Van Dam EW, Roelfsema F, Veldhuis JD, Helmerhorst FM, Frolich M, Meinders AE, Krans HM, Pijl H (2002) Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. Am J Physiol Endocrinol Metab 282:E865–E872
102. Laughlin GA, Morales AJ, Yen SS (1997) Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia. J Clin Endocrinol Metab 82:1692–1696
103. Mantzoros CS, Dunaif A, Flier JS (1997) Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 82:1687–1691
104. Muneyvirci-Delale O, Nacharaju VL, Altura BM, Altura BT (1998) Sex steroid hormones modulate serum ionized magnesium and Ca levels throughout the menstrual cycle in women. Fertil Steril 69:958–962
105. Rumawas ME, McKeown NM, Rogers G, Meigs JB, Wilson PWF, Jacques PF (2006) Magnesium intake is related to improved insulin homeostasis in the Framingham offspring cohort. J Am Coll Nutr 25:486–492
106. Chakraborty P, Ghosh S, Goswami SK, Syed NK, Baidyanath C, Kuladip J (2013) Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res 152:9–15
107. Kauffman RP, Tullar PE, Nipp RD, Castracane VD (2011) Serum magnesium concentrations and metabolic variables in polycystic ovary syndrome. Acta Obstet Gynecol Scand 90:452–458
108. Kurdoglu Z, Kurdoglu M, Demir H, Sahin HG (2012) Serum trace elements and heavy metals in polycystic ovary syndrome. Hum Exp Toxicol 31(5):452–456. doi:10.1177/0960327111424299
109. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JMC, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 86:2453–2455
110. Slesinski RS, Clarke JJ, San RH, Gudi R (2005) Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells. Mutat Res 585:86–95
111. Cefalu WT, Hu FB (2004) Role of chromium in human health and in diabetes. Diabetes Care 11:2741–2751
112. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A (1977) Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 30:531–538
113. Mertz W (1998) Chromium research from a distance: from 1959 to 1980. J Am Coll Nutr 17:544–547
114. Davis CM, Vincent JB (1997) Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36:4382–4385
115. Vincent JB (1999) Mechanisms of chromium action: low-molecular-weight chromium-binding substance. J Am Coll Nutr 18:6–12
116. Morris BW, MacNeil S, Hardisty CA, Heller S, Burgin C, Gray TA (1999) Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 13:57–61
117. Lydic ML, McNurlan M, Bembo S, Mitchell L, Komaroff E, Gelato M (2006) Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril 86:243–246
118. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C (2010) Vitamin D: a pleiotropic hormone. Kidney Int 78:140–145
119. Alvarez JA, Ashraf A (2010) Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010:351–385
120. Ngo DT, Chan WP, Rajendran S et al (2011) Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide 25:326–330
121. Ortlepp JR, Metrikat J, Albrecht M, von Korff A, Hanrath P, Hoffmann R (2003) The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 20:451–454
122. Bourlon PM, Billaudel B, Faure-Dussert A (1999) Influence of vitamin D3 deficiency and 1, 25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 160:87–95
123. Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820–825
124. Thomson RL, Spedding S, Buckley JD (2012) Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol 7:343–350
125. Homburg R, Amsterdam A (1998) Polycystic ovary syndrome—loss of the apoptotic mechanism in the ovarian follicles? J Endocrinol Invest 21:552–557
126. Bikle D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94:26–34
127. Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169–2180
128. Yildizhan R, Kurdoglu M, Adali E et al (2009) Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 280:559–563
129. Pal L, Berry A, Coraluzzi L (2012) Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol Endocrinol 28:965–968
130. Wehr E, Pieber TR, Obermayer-Pietsch B (2011) Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest 34:757–763
131. Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, Tuncel E, Erturk E, Imamoglu S (2010) The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 33:234–238
132. Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL (2004) Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J Clin Endocrinol Metab 89:615–620
133. Oh R (2005) Practical applications of fish oil (Omega-3 fatty acids) in primary care. J Am Board Fam Pract 18:28–36
134. Ebbesson SO, Risica PM, Ebbesson LO, Kennish JM, Tejero ME (2005) Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int J Circumpolar Health 64:396–408
135. Rafraf M, Mohammadi E, Asghari-Jafarabadi M, Farzadi L (2012) Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome. J Am Coll Nutr 31:361–368
136. Kratz M, Swarbrick MM, Callahan HS, Matthys CC, Havel PJ, Weigle DS (2008) Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr 87:347–353
137. Mohammadi E, Rafraf M, Farzadi L, Asghari-Jafarabadi M, Sabour S (2012) Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome. Asia Pac J Clin Nutr 21(4):511–518
138. Gillies CL, Abrams KR, Lambert PC et al (2007) Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334:299
139. Colberg SR, Albright AL, Blissmer BJ et al (2010) Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. Exercise and type 2 diabetes. Med Sci Sports Exerc 42:2282–2303
140. Lee S, Kuk JL, Davidson LE et al (2005) Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without Type 2 diabetes. J Appl Physiol 99:1220–1225
141. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ (2009) Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 92:1966–1982
142. Bianchi C, Miccoli R, Penno G, Del Prato S (2008) Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care 31:208–214
143. Kiddy DS, Hamilton-Fairley D, Bush A et al (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105–111
144. Clark AM, Ledger W, Galletly C et al (1995) Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10:2705–2712
145. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD (2009) The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 24:1976–1981
146. Holte J, Bergh T, Berne C, Wide L, Lithell H (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:2586–2593
147. Moran LJ, Hutchison SK, Norman RJ, Teede HJ (2011) Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 7:CD007506. doi:10.1002/14651858.CD007506
148. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M et al (2013) Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet 113(4):520–545. doi:10.1016/j.jand.2012.11.018
149. Douglas CC, Gower BA, Darnell BE, Ovalle F, Oster RA, Azziz R (2006) Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril 85:679–688
150. Mehrabani HH, Salehpour S, Amiri Z, Farahani SJ, Meyer BJ, Tahbaz F (2012) Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. J Am Coll Nutr 31:117–125
151. Graff SK, Mário FM, Alves BC, Spritzer PM (2013) Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes. Fertil Steril 100:1081–1088
152. Leidy HJ, Racki EM (2010) The addition of a protein-rich breakfast and its effects on acute appetite control and food intake in ‘breakfast-skipping’ adolescents. Int J Obes 34:1125–1133
153. Zumoff B, Freeman R, Coupey S, Saenger P, Markowitz M, Kream J (1983) A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N Engl J Med 309:1206–1209
154. Prelevic GM, Wurzburger MI, Balint-Peric L (1993) 24-hour serum cortisol profiles in women with polycystic ovary syndrome. Gynecol Endocrinol 7:179–184
155. Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, Pasquali R, Erwin P, Bodde A, Montori VM, Murad MH (2013) Lifestyle modification programs in polycystic ovary syndrome: Systematic review and meta-analysis. J Clin Endocrinol Metab 98(12):4655–4663. doi:10.1210/jc.2013-2385
156. Brown AJ, Setji TL, Sanders LL, Lowry KP, Otvos JD, Kraus WE, Svetkey PL (2009) Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. Med Sci Sports Exerc 41:497–504
157. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ (1994) Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility, Sterility 61:598–604
158. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS (2004) A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82:421–429
159. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS (2008) The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93:4299–4306
160. Karimzadeh MA, Javedani M (2010) An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril 94:216–220
161. Palomba S, Falbo A, Giallauria F, Russo T, Rocca M, Tolino A, Zullo F, Orio F (2010) Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 25:2783–2791
162. Qublan HS, Yannakoula EK, Al-Qudah MA, El-Uri FI (2007) Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med J 28:1694–1699
163. Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB (2009) Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol Regul Integr Comp Physiol 297:R387–R395
164. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, De Lorenzo A, Tafuri D, Lombardi G, Colao A, Orio F (2007) Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 92:1379–1384